Cargando…
NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS
In light chain amyloidosis, a reduction in dFLC to below 40 mg/l is a prerequisite for organ recovery as nearly half of the patients who achieve very good partial haematological responses have improvement in the function of the involved organ. We describe a patient who developed new-onset cardiac am...
Autores principales: | Idowu, Abiodun, Tung, Lillian, Chu, Catherine, Skeete, Jamario, Paner, Agne, Okwuosa, Tochukwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035620/ https://www.ncbi.nlm.nih.gov/pubmed/36970162 http://dx.doi.org/10.12890/2023_003768 |
Ejemplares similares
-
Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022) -
AL Amyloidosis
por: Desport, Estelle, et al.
Publicado: (2012) -
Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis
por: Kim, Darae, et al.
Publicado: (2020) -
Cardiac Amyloidosis
por: Elbdri, Salah, et al.
Publicado: (2021) -
Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)